Semnur Pharmaceuticalsincis A Specialty Pharmaceutical Company Focused On The Clinical And Commercial Development Of Innovative Products And Therapeutics That Meet The Needs Of Pain Management Practitioners And Their Patientsour Primary Focus Lies In The Development Of Non Opioid Products For Meeting The Needs Of Under Served Patients With Back Painwe Believe We Have The Technology To Improve Productsefficacy And Safety And Make A Critical Difference In The Treatment Of Back Pain Patientswe At Semnur Are Very Excited To Receive Fast Track Status From The Fda For Our Novel Injectable Gel Formulation Sp 102 In Development And Announce The Start Of Our Phase 3 Multi Center Clear Trial In Sciatica Lumbar Radicular Painhttps Clinicaltrials Gov Ct2 Show Nct03372161 Term=Semnur&Recrs=Ab&Rank=1In The U S More Than 30 Million People Live With Chronic Low Back And Radicular Sciatica Painand Many Experience Debilitating Pain At Moderate To Severe Levels With Intolerance And Or Inadequate Response To Current Analgesic Therapies Such As Opioids And Nonsteroidal Anti Inflammatory Drugsnsaids There Is A Great Need For Highly Effective Analgesic And Anti Inflammatory Medications To Provide Patient Relief Without The Toxicity And Tolerability Challenges Of Nsaids And Opioids Opioid Prescriptions Account For About 60 Percent Of The Chronic Pain Market And Commonly Prescribed For Low Back Pain But Carry A Well Known Risk Of Abuse And Misuseunderscoring The Need For Alternative Pain Therapies Without The Medical And Societal Challenges In The United Statessemnur Is Planning To Develop And Commercialize Product Candidateseither Through Its Own Efforts Or In Conjunction With Partnersoutside Of The United Statessemnur Anticipates Commercializing These Products On A Worldwide Basis Through Select Regional Partnerships
